Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions.
Chen WS, Tetzlaff MT, Diwan H, Jahan-Tigh R, Diab A, Nelson K, Glitza IC, Kaunitz GJ, Johnson D, Torres-Cabala C, Pacha O, Taube JM, Maloney K, Prieto VG, Curry JL. Chen WS, et al. Among authors: pacha o. J Cutan Pathol. 2018 Oct;45(10):764-773. doi: 10.1111/cup.13312. Epub 2018 Jul 24. J Cutan Pathol. 2018. PMID: 29943453
Skin Reactions to Immune Checkpoint Inhibitors.
Patel AB, Pacha O. Patel AB, et al. Among authors: pacha o. Adv Exp Med Biol. 2017;995:175-184. doi: 10.1007/978-3-319-53156-4_9. Adv Exp Med Biol. 2017. PMID: 28321818 Review.
Skin Reactions to Immune Checkpoint Inhibitors.
Patel AB, Pacha O. Patel AB, et al. Among authors: pacha o. Adv Exp Med Biol. 2018;995:117-129. doi: 10.1007/978-3-030-02505-2_5. Adv Exp Med Biol. 2018. PMID: 30539508 Review.
Skin Reactions to Immune Checkpoint Inhibitors.
Patel AB, Pacha O. Patel AB, et al. Among authors: pacha o. Adv Exp Med Biol. 2020;1244:235-246. doi: 10.1007/978-3-030-41008-7_11. Adv Exp Med Biol. 2020. PMID: 32301018 Review.
Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit.
Patel AB, Farooq S, Welborn M, Amaria RN, Chon SY, Diab A, Glitza Oliva IC, Huen AO, Li SQ, Nelson KC, Pacha O, Patel SP, Rapini RP, Tawbi HA, Wong MK, McQuade J, Davies MA, Haydu LE. Patel AB, et al. Among authors: pacha o. Cancer. 2022 Mar 1;128(5):975-983. doi: 10.1002/cncr.34004. Epub 2021 Nov 1. Cancer. 2022. PMID: 34724197 Free article.
Skin Reactions to Immune Checkpoint Inhibitors.
Patel AB, Pacha O. Patel AB, et al. Among authors: pacha o. Adv Exp Med Biol. 2021;1342:319-330. doi: 10.1007/978-3-030-79308-1_11. Adv Exp Med Biol. 2021. PMID: 34972971 Review.
Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune-related adverse event reveal upregulation of toll-like receptor 4/complement-induced innate immune response and increased density of TH 1 T-cells.
Marques-Piubelli ML, Seervai RNH, Mudaliar KM, Ma W, Milton DR, Wang J, Muhlbauer A, Parra ER, Solis LM, Nagarajan P, Speiser J, Hudgens C, Cho WC, Aung PP, Patel A, Pacha O, Nelson KC, Tetzlaff MT, Amaria RN, Torres-Cabala CA, Prieto VG, Wistuba II, Curry JL. Marques-Piubelli ML, et al. Among authors: pacha o. J Cutan Pathol. 2023 Jul;50(7):661-673. doi: 10.1111/cup.14442. Epub 2023 May 7. J Cutan Pathol. 2023. PMID: 37150813
28 results